In this issue:
Breast-conserving surgery ± RT in early breast cancer
Trastuzumab deruxtecan vs. emtansine for HER2+ metastatic breast cancer
Oncolytic virotherapy + neoadjuvant chemotherapy in nonmetastatic TNBC
EP vs. EC-P in operable HER2–, lymph node+ breast cancer
Statin use: cancer and noncancer survival in breast cancer
Neighbourhood disadvantage and breast cancer-specific survival
OS with CDK4/6 inhibitors in hormone receptor+ metastatic breast cancer
APBI vs. whole-breast RT for early breast cancer
Adjuvant paclitaxel and trastuzumab for node–, HER2+ breast cancer
Tucatinib + trastuzumab-capecitabine for HER2+ breast cancer with brain metastases
Please login below to download this issue (PDF)